PURPOSE: The aim of this study was to analyze receptor tyrosine kinases (RTK) and their downstream signaling activation profile in myxoid liposarcomas (MLS) by investigating 14 molecularly profiled tumors: 7 naive and 7 treated with conventional chemotherapy/radiotherapy or the new drug trabectedin. EXPERIMENTAL DESIGN: Frozen and matched formalin-fixed, paraffin-embedded material from surgical specimens were analyzed using biochemical, molecular, and molecular/cytogenetic approaches, complemented by immunohistochemistry and confocal microscopy. RESULTS: In the absence of any RTK and downstream effector deregulation, the naive cases revealed epidermal growth factor receptor, platelet-derived growth factor receptor B, RET, and MET activation sustained by autocrine/paracrine loops, and RTK cross-talk as a result of heterodimerization. Interestingly, RET and MET activation seems to play a major role in the pathogenesis of MLS by involving different targets through different mechanisms. RET activation (which may activate MET) involves the tumoral vascular component by means of RET/MET cross-talk and VEGFA (vascular endothelial growth factor A)/GFRalpha3 (glial cell-derived neurotrophic factor family receptor alpha3)/artemin-mediated signaling as revealed by VEGF receptor 2/RET coimmunoprecipitation. MET activation involves the cellular tumor component by means of a direct ligand-dependent loop and indirect GFRalpha3 (RET coreceptor)/artemin-mediated signaling. About downstream signaling, the association of AKT activation with the round cell variant is interesting. No relevant changes in the original RTK activation profiles were observed in the posttreatment cases, a finding that is in keeping with the nontargeted treatments used. CONCLUSIONS: These findings highlight the particular cell-specific activation profile of RET/GFRalpha3 and MET in MLS, and the close correlation between AKT activation and the round cell variant, thus opening up new therapeutic perspectives for MET/AKT inhibitors and antagonistic small molecules binding GFRalpha3. Copyright 2010 AACR.
PURPOSE: The aim of this study was to analyze receptor tyrosine kinases (RTK) and their downstream signaling activation profile in myxoid liposarcomas (MLS) by investigating 14 molecularly profiled tumors: 7 naive and 7 treated with conventional chemotherapy/radiotherapy or the new drug trabectedin. EXPERIMENTAL DESIGN: Frozen and matched formalin-fixed, paraffin-embedded material from surgical specimens were analyzed using biochemical, molecular, and molecular/cytogenetic approaches, complemented by immunohistochemistry and confocal microscopy. RESULTS: In the absence of any RTK and downstream effector deregulation, the naive cases revealed epidermal growth factor receptor, platelet-derived growth factor receptor B, RET, and MET activation sustained by autocrine/paracrine loops, and RTK cross-talk as a result of heterodimerization. Interestingly, RET and MET activation seems to play a major role in the pathogenesis of MLS by involving different targets through different mechanisms. RET activation (which may activate MET) involves the tumoral vascular component by means of RET/MET cross-talk and VEGFA (vascular endothelial growth factor A)/GFRalpha3 (glial cell-derived neurotrophic factor family receptor alpha3)/artemin-mediated signaling as revealed by VEGF receptor 2/RET coimmunoprecipitation. MET activation involves the cellular tumor component by means of a direct ligand-dependent loop and indirect GFRalpha3 (RET coreceptor)/artemin-mediated signaling. About downstream signaling, the association of AKT activation with the round cell variant is interesting. No relevant changes in the original RTK activation profiles were observed in the posttreatment cases, a finding that is in keeping with the nontargeted treatments used. CONCLUSIONS: These findings highlight the particular cell-specific activation profile of RET/GFRalpha3 and MET in MLS, and the close correlation between AKT activation and the round cell variant, thus opening up new therapeutic perspectives for MET/AKT inhibitors and antagonistic small molecules binding GFRalpha3. Copyright 2010 AACR.
Authors: Marieke A de Graaff; Jamie S E Yu; Hannah C Beird; Davis R Ingram; Theresa Nguyen; Jeffrey Juehui Liu; Svetlana Bolshakov; Károly Szuhai; Pierre Åman; Keila E Torres; Dina Lev; Torsten O Nielsen; Judith V M G Bovée; Alexander J Lazar; Neeta Somaiah Journal: Lab Invest Date: 2016-06-06 Impact factor: 5.662
Authors: Elizabeth Charytonowicz; Melissa Terry; Katherine Coakley; Leonid Telis; Fabrizio Remotti; Carlos Cordon-Cardo; Robert N Taub; Igor Matushansky Journal: J Clin Invest Date: 2012-02-01 Impact factor: 14.808
Authors: Liam A McDonnell; Judith V M G Bovée; Bram Heijs; Stephanie Holst-Bernal; Marieke A de Graaff; Inge H Briaire-de Bruijn; Mar Rodriguez-Girondo; Michiel A J van de Sande; Manfred Wuhrer Journal: Lab Invest Date: 2020-04-27 Impact factor: 5.662
Authors: Wei-Lien Wang; Daniela Katz; Dejka M Araujo; Vinod Ravi; Joseph A Ludwig; Jonathan C Trent; Shreyaskumar R Patel; Patrick P Lin; Ashleigh Guadagnolo; Dolores Lòpez-Terrada; Angelo Paola Dei Tos; Valerie O Lewis; Dina Lev; Raphael E Pollock; Gunar K Zagars; Robert S Benjamin; John E Madewell; Alexander J Lazar Journal: Clin Sarcoma Res Date: 2012-12-29
Authors: Elizabeth G Demicco; Keila E Torres; Markus P Ghadimi; Chiara Colombo; Svetlana Bolshakov; Aviad Hoffman; Tingsheng Peng; Judith V M G Bovée; Wei-Lien Wang; Dina Lev; Alexander J Lazar Journal: Mod Pathol Date: 2011-10-21 Impact factor: 7.842
Authors: Katja Schmitz; Hartmut Koeppen; Elke Binot; Jana Fassunke; Helen Künstlinger; Michaela A Ihle; Carina Heydt; Eva Wardelmann; Reinhard Büttner; Sabine Merkelbach-Bruse; Josef Rüschoff; Hans-Ulrich Schildhaus Journal: PLoS One Date: 2015-04-06 Impact factor: 3.240
Authors: A Nabeshima; Y Matsumoto; J Fukushi; K Iura; T Matsunobu; M Endo; T Fujiwara; K Iida; Y Fujiwara; M Hatano; N Yokoyama; S Fukushima; Y Oda; Y Iwamoto Journal: Br J Cancer Date: 2015-01-06 Impact factor: 7.640